1. Home
  2. |Insights
  3. |No End in Sight: The Long Tail of COVID Relief Fraud Enforcement

No End in Sight: The Long Tail of COVID Relief Fraud Enforcement

Client Alert | less than 1 min read | 08.15.23

Although the COVID-19 public health declaration officially ended in May, government investigations of pandemic relief fraud are from over. As observed in a recent report by the Small Business Administration Office of Inspector General, investigations will likely ensue for years to come in light of Congress’s decision to extend the statute of limitations to ten years for pandemic relief fraud.    

In an Expert Analysis article published in Law360, C&M attorneys analyze recent enforcement trends and discuss practical steps that companies can take to mitigate risks should they find themselves under investigation or a defendant in a False Claims Act suit involving COVID relief loans.

Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...

View All Insights